BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

WuXi AppTec, Inc. Selects H-Cube from Thales Nanotechnology, Inc. for Laboratory-based Hydrogenation


1/7/2009 8:40:47 AM

SHANGHAI, China, BUDAPEST, Hungary and PRINCETON, N.J., Jan. 6 /PRNewswire/ -- WuXi AppTec, the operating company of WuXi PharmaTech, a leading pharmaceutical, biotechnology and medical device research and development outsourcing company with operations in China and the United States, today announced its selection of H-Cube from ThalesNano Inc. for laboratory-based hydrogenation. WuXi joins all of the top 20 pharmaceutical companies worldwide that have introduced and adopted the H-Cube technology.

"WuXi Apptec is one of the largest CRO companies in the world, providing best in class services to pharmaceutical, biotechnology and medical device research and development industries. We are delighted to supply WuXi with our technology and services," commented Dr. Laszlo Urge, CEO of ThalesNano Inc.

"We are very pleased to deploy H-Cube. Hydrogenation in flow for drug discovery is a significantly more productive and safer approach than traditional batch-based techniques. We are looking forward to working with ThalesNano as we move to larger scale in the future," commented Shuhui Chen, Chief Scientific Officer of WuXi AppTec.

The H-Cube Continuous-flow Hydrogenation Reactor is a bench-top standalone hydrogenation device, uniquely combining continuous-flow microchemistry with endogenous on-demand hydrogen generation and a disposable catalyst cartridge system. Compared to conventional methods, it allows safer, faster and more cost-efficient hydrogenation with superior yield. The H-Cube and the other novel Cube series flow reactor systems developed by ThalesNano Inc. are showing tremendous benefits in the drug discovery process including shortened development time, increased cost efficiency and reduced environmental impact.

For more information please go to: www.thalesnano.com

About ThalesNano Inc.:

ThalesNano is a world-leading provider of continuous process chemistry instruments in the rapidly developing market of laboratory and process scale flow reactors. The company has the widest portfolio of bench-top continuous process instruments. Its R&D 100 award winning H-Cube(R) continuous-flow hydrogenation reactor and the pilot plant scale version H-Cube Midi(TM) are used in hundreds of laboratories in four continents and have become the new industry standard for hydrogenation.

CONTACT: Laszlo Urge, Ph.D., CEO of ThalesNano, +36-1-880-8500,
ceodirect@thalesnano.com

Web site: http://www.thalesnano.com/



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES